Boston Scientific has just reported Q2 earnings today — and the stock's 6.6% rally on the week tells only part of the story, because analysts are still cutting targets even as they hold their Buy ratings.
The analyst picture is the week's defining tension. Every firm that has moved on BSX over the past two weeks has lowered its price target — none have cut their rating. UBS assumed coverage yesterday at Buy with a $74 target, down sharply from the prior analyst's $95. Oppenheimer trimmed to $85 from $90 the day before, maintaining Outperform. Earlier in the month, Mizuho cut to $70 from $90, RBC to $85 from $100, Needham to $57 from $77. The mean target now sits at $72.31, against a current price of $46.06 — implying roughly 57% upside on paper. That gap is less a signal of conviction than a reflection of how fast targets are being revised down without ratings following. The analyst recommendation differential factor ranks in the 94th percentile, meaning consensus is leaning bullish relative to the universe — but the direction of travel on price targets has been relentlessly lower.
Options positioning reinforces the relatively calm tone rather than flagging distress. The put/call ratio runs at 0.37, fractionally below its 20-day average of 0.38 and near the middle of its 52-week range of 0.28 to 1.10. There is no unusual hedging activity ahead of today's print — options traders are not loading up on downside protection. The borrow market tells the same story. Availability is extraordinarily loose at 8,638% — nearly 1.5 billion shares remain available to borrow against roughly 27.6 million shares short. Cost to borrow has edged up about 4.7% on the week to 0.43%, but that is still well under half a percent, essentially free to borrow. Short interest itself has fallen nearly 50% over the past month, from above 53 million shares in mid-June to 27.6 million now, and sits at just 1.9% of the free float. There is no meaningful short-side pressure on this name.
The bull and bear debate centres on product-line dynamics rather than macro or balance-sheet risk. Bulls point to the atrial fibrillation procedure market, where trial results have set up an anticipated 5-10% volume increase and the global AFib market has a credible path from $9 billion to $15 billion by 2028. Boston Scientific's electrophysiology and LAAC portfolio sits at the centre of that opportunity. Bears counter with market share erosion — RF ablation procedures projected to fall from 34% to 23% of the mix by 2030, cryoablation from 25% to 20% — alongside pricing pressure and elevated debt. The PE multiple has moved up to 12.9x on the back of this week's rally, with the EV/EBITDA sitting at 11.2x; neither looks stretched if the AFib growth case plays out, but both are under scrutiny if procedure volumes disappoint. The EPS surprise factor scores at the 73rd percentile, meaning the company has a reasonable track record of beating estimates — relevant context given that the prior Q1 print on April 30 produced a modest 1.1% one-day decline.
Director-level buying in May adds a further layer of context. Three board members — including Lead Independent Director Edward Ludwig — bought shares in the $55-57 range on May 19-20, for a combined outlay of around $554,000. Those purchases now sit roughly 18% underwater at today's price, which makes them a data point about sentiment at the time rather than a profit signal now. The 90-day net insider position is modestly positive at 12,689 shares, though the transactions are largely small and include award-related sells.
BSX rallied alongside medtech peer MDT, which gained 5.5% on the week, while IRTC added 7.7% — suggesting a broader sector bid rather than a BSX-specific catalyst. The question now is whether today's actual Q2 numbers — reported this morning — are enough to slow or reverse the six-week trend of analyst target reductions, or whether the post-earnings reset simply begins the next round of downgrades.
See the live data behind this article on ORTEX.
Open BSX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
